Ariceum Therapeutics GmbH has submitted an application with the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial of [123I]-ATT-001, its iodine-123-labeled PARP inhibitor in patients with recurrent glioblastoma.

Inflammasomes are essential components of the innate immune system with a multiprotein structure.

The molecular mechanisms of activation of trace amine-associated receptor 1 (TAAR1) are still not clearly understood.

Vantai Inc. has entered into an amended and restated collaboration and license agreement with Blueprint Medicines Corp. to design and advance novel targeted protein degrader therapies.

Corbus Pharmaceuticals Holdings Inc. has obtained FDA clearance of its IND application for CRB-601, a TGF-β-blocking monoclonal antibody targeting the integrin αvβ8. Enrollment in a first-in-human phase I study will open in the first half of this year.

There is a strong relationship between heart failure (HF) and atrial fibrillation (AF): half of the patients with HF acquire AF. Recent studies discovered a genetic basis underlying AF, which demonstrated a strong heritable component to this disease.

Alzheimer’s disease (AD) can be divided into five distinct subtypes based on protein expression levels measured in the cerebrospinal fluid (CSF). The subtypes were associated with different genetic risk factors and are likely to benefit from different treatment approaches. Many clinicians, drug developers and the general public still “think of Alzheimer’s as a single disease entity, and that suggests that every patient needs to have the same medication,” Betty Tijms told BioWorld.